All News

Further, the authors of the “Standards of Care in Diabetes 2025” highlighted the benefits of continuous glucose monitoring systems and recommend initiating these as soon as possible.

Researchers explore trends from 2014 to 2022 among pediatric invasive pneumococcal diseases since introduction of the 13-valent pneumococcal conjugate vaccine.

The authors emphasize the importance of multifaceted and team-based approaches to the management of diabetes.

Investigators find that orforglipron lowered A1c by an average of 1.3% to 1.6% from a baseline of 8% across 3 different dosages.

From 1990 to 2021, researchers explored the global burden of atopic dermatitis among older adults.

Crystal Hodge discusses being transparent about adverse effects of the MMR vaccine and educating patients about measles.

The approval is based on 2 phase 3 studies demonstrating reductions in itch severity and urticaria activity as a composite of itch and hives at 24 weeks.

Luke Turnock, PhD, MSc, discussed current trends in the promotion of lifestyle enhancement drugs for populations they are not approved for.

Researchers conduct a review to understand the efficacy and safety of topical minocycline for the treatment of moderate to severe papulopustular rosacea.

Crystal Hodge discusses R naughts and the measures of how contagious measles is.

The recommendation includes patients 12 years and older traveling to a country where there is a chikungunya outbreak or where there is an elevated risk for US travelers.

Currently, the recommendation is for patients 75 years and older and those aged 60 to 74 years with an increased risk of severe respiratory syncytial virus.

The 14-section order focuses on a variety of policy changes intended to make patients’ out-of-pocket costs for prescription medications more affordable in the US.

The FDA approved Penmenvy in February 2025 for use in patients aged 10 to 25 years.

The subgroup analysis shows adolescents treated with the drug once daily had higher rates of clear or almost clear skin compared to patients receiving the placebo.

Over 20 years since skin of color dermatology was introduced, researchers explored advancements and what is yet to come in the future.

The drug is approved for the short-term treatment of acute repetitive seizures, also known as seizure clusters, which differ from a patient’s normal seizure pattern.

At AAP 2025, Melanie Maxwell, president of AlignRx, discussed the intent, benefits and consequences of the IRA.

On behalf of 39 state and territory attorneys general, the National Association of Attorneys General issued a letter to Congress regarding major PBMs’ conflicts of interest.

Mark Garofoli, PharmD, MBA, BCGP, CPE, CTTS, discusses effective strategies for balancing excellent patient care with strict regulations surrounding controlled substances.

The FDA approved adalimumab-aaty in May 2023 for 8 indications, including rheumatoid arthritis, psoriatic arthritis, Crohn disease, ulcerative colitis, and plaque psoriasis.

One asymptomatic patient did experience drug-induced liver injury that was resolved after discontinuation of danuglipron.

At AAP 2025, Douglas Hoey, CEO of NCPA, discussed the possibility of PBM reform under the new administration and his take on Optum Rx’s plans to introduce a cost-plus reimbursement model.

In a telephone audit, researchers attempted to quantify the frequency of patient barriers when looking to purchase sterile syringes from community pharmacies for over-the-counter use.

First-in-class brensocatib has the potential to be the first approved treatment for bronchiectasis.

With transitions of care inclusive of multiple health care settings, each provider must play a specific role to ensure overall improved patient outcomes.

Researchers explored TikTok’s role in the dissemination of information regarding isotretinoin and its users.

At AAP 2025, Ron Friedman discussed best practices for responding to a DEA inspection, how to identify any red flags, and best practices for dispensing.

However, patients should still be monitored for potential serious adverse effects, as investigators identified potential new concerns.

Furthermore, C-reactive protein has greater prognosis for lung cancer, colorectal cancer, and ovarian cancer.